{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:07:05Z","timestamp":1788937625168,"version":"build-2803163510"},"reference-count":26,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Int"],"DOI":"10.3892\/mi.2026.336","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:41:15Z","timestamp":1786444875000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Methotrexate subcutaneous injection for the initial treatment of rheumatoid arthritis can achieve earlier remission compared with oral administration"],"prefix":"10.3892","volume":"6","author":[{"given":"Yukie","family":"Saio","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Toho Hospital, Midori, Gunma 379\u20112311, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"key20260909093729_b1-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/mr\/roac156","article-title":"Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"key20260909093729_b2-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20260909093729_b3-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/ard.2003.011593","article-title":"Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis","volume":"63","author":"Wegrzyn","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20260909093729_b4-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis: Secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheumatol"},{"key":"key20260909093729_b5-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1093\/rheumatology\/keaf054","article-title":"Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA","volume":"64","author":"Qiao","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"e0221823","key":"key20260909093729_b6-MI-6-5-00336","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221823","article-title":"Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis","volume":"14","author":"Bujor","year":"2019","journal-title":"PLoS One"},{"key":"key20260909093729_b7-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"key20260909093729_b8-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"e74148","key":"key20260909093729_b9-MI-6-5-00336","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74148","article-title":"Clinical characteristics of young-onset versus elderly-onset rheumatoid arthritis: A systematic review and meta-analysis","volume":"16","author":"Acu\u00f1a-Rocha","year":"2024","journal-title":"Cureus"},{"key":"key20260909093729_b10-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"115","DOI":"10.31138\/mjr.140423.sat","article-title":"Should all patients trial subcutaneous methotrexate prior to commencing biologic therapy? A real world study","volume":"35","author":"Mirza","year":"2023","journal-title":"Mediterr J Rheumatol"},{"issue":"18715","key":"key20260909093729_b11-MI-6-5-00336","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75655-9","article-title":"Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis","volume":"10","author":"Hayashi","year":"2020","journal-title":"Sci Rep"},{"key":"key20260909093729_b12-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: Clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pavy","year":"2006","journal-title":"Joint Bone Spine"},{"key":"key20260909093729_b13-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/mr\/roac103","article-title":"Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"key20260909093729_b14-MI-6-5-00336","first-page":"S1046","article-title":"POS1386-HPR effectiveness of subcutaneous methotrexate in patients with rheumatoid arthritis and its persistence in the long term","volume":"82 (Suppl 1)","author":"Villarreal","year":"2023","journal-title":"Anna Rheum Dis"},{"key":"key20260909093729_b15-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/acr.23927","article-title":"Treatment strategies in early rheumatoid arthritis methotrexate management: Results from a prospective cohort","volume":"72","author":"Moura","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key20260909093729_b16-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1093\/rheumatology\/keq216","article-title":"Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"key20260909093729_b17-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3899\/jrheum.110481","article-title":"Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis","volume":"38","author":"Stamp","year":"2011","journal-title":"J Rheumatol"},{"key":"key20260909093729_b18-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00228-015-1819-x","article-title":"The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies-a systematic review","volume":"71","author":"Mohamed","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"key20260909093729_b19-MI-6-5-00336","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J Rheumatol"},{"key":"key20260909093729_b20-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: Drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"64","key":"key20260909093729_b21-MI-6-5-00336","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00455-4","article-title":"Prefilled pen versus prefilled syringe: A pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA","volume":"18","author":"Roszkiewicz","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"key20260909093729_b22-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/PPA.S64111","article-title":"Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: Patient preference and comparison of the self-injection experience","volume":"8","author":"Demary","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"2050312114564241","key":"key20260909093729_b23-MI-6-5-00336","doi-asserted-by":"publisher","DOI":"10.1177\/2050312114564241","article-title":"Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis","volume":"2","author":"Pachon","year":"2014","journal-title":"SAGE Open Med"},{"key":"key20260909093729_b24-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-017-0057-3","article-title":"Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis","volume":"4","author":"Hudry","year":"2017","journal-title":"Rheumatol Ther"},{"key":"key20260909093729_b25-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40744-018-0134-2","article-title":"Use of auto-injector for methotrexate subcutaneous self-injections: High satisfaction level and good compliance in SELF-I study, a randomized, open-label, parallel group study","volume":"6","author":"Saraux","year":"2019","journal-title":"Rheumatol Ther"},{"key":"key20260909093729_b26-MI-6-5-00336","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine International"],"original-title":[],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:37:35Z","timestamp":1788935855000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mi.2026.336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.3892\/mi.2026.336","relation":{},"ISSN":["2754-3242","2754-1304"],"issn-type":[{"value":"2754-3242","type":"print"},{"value":"2754-1304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}